Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance

Current Opinion in Pharmacology(2020)10.1016/j.coph.2020.06.001Source: DataRank Database

Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance is a research paper published in Current Opinion in Pharmacology (2020). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.70)OA: greenTopics (49)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Evan C. Ray ORCID

Live enrichment

PubMed:32682281 PMC:PMC8061532 OpenAlex:https://openalex.org/W3042662343

National Institutes of Health

Grant: NIDDK K08 DK110332

NIDDK NIH HHS

Grant: K08 DK110332

National Institutes of Health

Grant: 3K08DK110332-05S1

Proteolytic activation of ENaC in Proteinuric Kidney Disease

FWCI

1.70

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8061532

publisherhttps://api.elsevier.com/content/article/PII:S1471489220300242?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1471489220300242?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.coph.2020.06.001

Fields of Study

Diabetes Treatment and ManagementPotassium and Related DisordersMagnesium in Health and Disease03 medical and health sciences0302 clinical medicineAnimalsCardiovascular DiseasesDiabetes ComplicationsHeartHumansKidneyKidney DiseasesMagnesiumProtective AgentsSodium-Glucose Transporter 2 InhibitorsUric Acid

MeSH Terms

Sodium-Glucose Transporter 2 InhibitorsAnimalsCardiovascular DiseasesHeartHumansKidneyKidney DiseasesMagnesiumUric AcidProtective AgentsDiabetes Complications

Keywords

MedicineGlycemicDiabetes mellitusRenal functionHeart failureUric acidInternal medicineKidney diseaseType 2 diabetesDiuresisKidneyCardiologyEndocrinologyHeartProtective AgentsDiabetes ComplicationsCardiovascular DiseasesAnimalsHumansKidney DiseasesMagnesiumSodium-Glucose Transporter 2 Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being